Výsledky vyhledávání - "Jos B, Poell"

Akademický článek

Hallmarks of a genomically distinct subclass of head and neck cancer

Autor: Tara Muijlwijk, Irene H. Nauta, Anabel van der Lee, Kari J. T. Grünewald, Arjen Brink, Sonja H. Ganzevles, Robert J. Baatenburg de Jong, Lilit Atanesyan, Suvi Savola, Mark A. van de Wiel, Laura A. N. Peferoen, Elisabeth Bloemena, Rieneke van de Ven, C. René Leemans, Jos B. Poell, Ruud H. Brakenhoff

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)

Abstract Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key characteristics of cancer development. Nonetheless, some tumors show hardly any CNAs, a remarka

Externí odkaz: https://doaj.org/article/225436245a4a4f2badda609a77918405

Zobrazit plný text záznamu

Akademický článek

Immune cell topography of head and neck cancer

Autor: Bernard A Fox, Rieneke van de Ven, Carmen Ballesteros-Merino, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans, Laura A N Peferoen, Elisabeth Bloemena, Fatima Ekhlas

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)

Background Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20% of patients respond.

Externí odkaz: https://doaj.org/article/706241e19a784c6ebfc691493690aafb

Zobrazit plný text záznamu

Akademický článek

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites

Autor: Bernard A Fox, Rieneke van de Ven, Yoshinobu Koguchi, Venkatesh Rajamanickam, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Arjen Brink, Changlin Ke, Joseph N Fass, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)

Background The response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%–18% for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Detailed understanding of the tumor i

Externí odkaz: https://doaj.org/article/4c0703b158e44abebdb94f559e449d18

Zobrazit plný text záznamu

Akademický článek

Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for Treatment Investigation

Autor: Leon J. Wils, Marijke Buijze, Marijke Stigter-van Walsum, Arjen Brink, Britt E. van Kempen, Laura Peferoen, Elisabeth R. Brouns, Jan G. A. M. de Visscher, Erik H. van der Meij, Elisabeth Bloemena, Jos B. Poell, Ruud H. Brakenhoff

Publikováno v: Cells, Vol 13, Iss 8, p 710 (2024)

Precancerous cells in the oral cavity may appear as oral potentially malignant disorders, but they may also present as dysplasia without visual manifestation in tumor-adjacent tissue. As it is currently not possible to prevent the malignant transform

Externí odkaz: https://doaj.org/article/3e7b6e6a86674cbab9464c02b77f3b5f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

1487 PD-1 expression on tumor-infiltrating T-lymphocytes as determinant of the head and neck cancer tumor immune microenvironment rather than anatomical site

Autor: Bernard A Fox, Yoshinobu Koguchi, Venkatesh Rajamanickam, Rieneke van de Ven, Tara Muijlwijk, Dennis NLM Nijenhuis, Sonja H Ganzevles, C Rene Leemans, Ruud H Brakenhoff, Arjen Brink, Changlin Ke, Joseph N Fass, Jos B Poell

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Externí odkaz: https://doaj.org/article/da94da7d1b4e46daaebcc7a69e23eee4

Zobrazit plný text záznamu

Akademický článek

At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma

Autor: Niels E. Wondergem, Dennis N. L. M. Nijenhuis, Jos B. Poell, C. René Leemans, Ruud H. Brakenhoff, Rieneke van de Ven

Publikováno v: Frontiers in Oral Health, Vol 2 (2021)

Background: Recent advances in immunotherapy for head and neck squamous cell carcinoma (HNSCC) have led to implementation of anti-programmed death receptor 1 (PD-1) immunotherapy to standard of care for recurrent/metastatic HNSCC. However, the majori

Externí odkaz: https://doaj.org/article/f98288047e844af49060e0428d38ea76

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání